Groundbreaking Surgical Robot Secures 110 Million Boost To Revolutionize Minimally Invasive Heart Valve Replacement

Capstan Medical Inc., a pioneering medical device company, has secured $110 million in funding for its surgical robot and catheter-delivered implants aimed at revolutionizing minimally invasive heart valve replacement procedures. The Santa Cruz, California-based startup now boasts over $150 million in total funding, solidifying its position as a leader in the field.

“We’re at an inflection point where robotics will play a consequential role in delivering life-saving solutions to millions of patients worldwide,” said Justin Butler, a partner at Eclipse, one of the leading investors in Capstan Medical’s Series C round. “Capstan is at the forefront of this wave with their robotic solutions for structural heart disease.”

The company is developing innovative technologies to replace diseased mitral and tricuspid heart valves, offering a less-invasive alternative to traditional open-heart surgery. The flagship product is focused on addressing the world’s leading cause of death – heart disease – which affects millions worldwide. With its cutting-edge robotic system and catheter-delivered implants, Capstan Medical aims to provide a game-changing solution for patients who are not eligible for conventional procedures.

CEO Maggie Nixon revealed that the company plans to conduct its first in-human mitral valve procedure by early next year, followed by an in-human tricuspid valve procedure in 2025. Capstan Medical also announced its intention to start a pivotal trial of its mitral system in 2026 and submit it to the U.S. Food and Drug Administration for review as soon as 2028.

The Series C round was led by Eclipse, with Yu Galaxy and Intuitive Ventures participating alongside first-time investor Gideon Strategic Partners. Intuitive Ventures is also an existing partner that has supported Capstan Medical since its inception. This funding injection will enable Capstan Medical to further accelerate its product development, regulatory submissions, and commercialization efforts.

Nixon emphasized that the company remains committed to its mission of delivering innovative solutions for patients with heart disease. “We’re maturing the business right now,” she said. “We brought in experts like Brian King on the finance side… and we’re in final rounds of interviews on a regulatory head as well.” This strategic move reflects Capstan Medical’s focus on building a strong team to drive its growth and success.

The funding news is a testament to Capstan Medical’s groundbreaking technology and its potential to transform the lives of millions of patients worldwide. As the medical device industry continues to evolve, companies like Capstan Medical are pushing the boundaries of innovation.